Acetyl-CoA and the regulation of metabolism: mechanisms and consequences L Shi, BP Tu Current opinion in cell biology 33, 125-131, 2015 | 772 | 2015 |
TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma L Goyal, L Shi, LY Liu, F Fece de la Cruz, JK Lennerz, S Raghavan, ... Cancer discovery 9 (8), 1064-1079, 2019 | 296 | 2019 |
Acetyl-CoA induces transcription of the key G1 cyclin CLN3 to promote entry into the cell division cycle in Saccharomyces cerevisiae L Shi, B Tu PNAS 110 (18), 7318-7323, 2013 | 153 | 2013 |
Trehalose is a key determinant of the quiescent metabolic state that fuels cell cycle progression upon return to growth L Shi, BM Sutter, X Ye, BP Tu Molecular biology of the cell 21 (12), 1982-1990, 2010 | 153 | 2010 |
Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma SK Saha, JD Gordan, BP Kleinstiver, P Vu, MS Najem, JC Yeo, L Shi, ... Cancer discovery 6 (7), 727-739, 2016 | 150 | 2016 |
Cycloheximide can distort measurements of mRNA levels and translation efficiency DA Santos, L Shi, BP Tu, JS Weissman Nucleic acids research 47 (10), 4974-4985, 2019 | 83 | 2019 |
Mutant IDH inhibits IFNγ–TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma MJ Wu, L Shi, J Dubrot, J Merritt, V Vijay, TY Wei, E Kessler, KE Olander, ... Cancer discovery 12 (3), 812-835, 2022 | 73 | 2022 |
Cycling transcriptional networks optimize energy utilization on a genome scale GZ Wang, SL Hickey, L Shi, HC Huang, P Nakashe, N Koike, BP Tu, ... Cell reports 13 (9), 1868-1880, 2015 | 63 | 2015 |
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma JM Cleary, S Raghavan, Q Wu, YY Li, LF Spurr, HV Gupta, DA Rubinson, ... Cancer discovery 11 (10), 2488-2505, 2021 | 58 | 2021 |
NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer T Weiss-Sadan, M Ge, M Hayashi, M Gohar, CH Yao, A de Groot, S Harry, ... Cell metabolism 35 (3), 487-503. e7, 2023 | 49 | 2023 |
Npr2 inhibits TORC1 to prevent inappropriate utilization of glutamine for biosynthesis of nitrogen-containing metabolites S Laxman, BM Sutter, L Shi, BP Tu Science signaling 7 (356), ra120-ra120, 2014 | 49 | 2014 |
Protein acetylation as a means to regulate protein function in tune with metabolic state L Shi, B Tu Biochemical Society Transactions 42 (4), 1037-1042, 2014 | 49 | 2014 |
Systematic identification of anticancer drug targets reveals a nucleus-to-mitochondria ROS-sensing pathway J Zhang, CM Simpson, J Berner, HB Chong, J Fang, Z Ordulu, ... Cell 186 (11), 2361-2379. e25, 2023 | 48 | 2023 |
EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion–positive cholangiocarcinoma Q Wu, Y Zhen, L Shi, P Vu, P Greninger, R Adil, J Merritt, R Egan, MJ Wu, ... Cancer discovery 12 (5), 1378-1395, 2022 | 46 | 2022 |
Biology of IDH mutant cholangiocarcinoma MJ Wu, L Shi, J Merritt, AX Zhu, N Bardeesy Hepatology 75 (5), 1322-1337, 2022 | 32 | 2022 |
Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. Cancer Discov. 2016; 6: 727–739. doi: 10.1158/2159-8290 SK Saha, JD Gordan, BP Kleinstiver, P Vu, MS Najem, JC Yeo, L Shi, ... CD-15-1442.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 25 | |
GATOR1 regulates nitrogenic cataplerotic reactions of the mitochondrial TCA cycle J Chen, BM Sutter, L Shi, BP Tu Nature chemical biology 13 (11), 1179-1186, 2017 | 21 | 2017 |
SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers L Shi, W Shen, MI Davis, K Kong, P Vu, SK Saha, R Adil, J Kreuzer, ... Nature cancer 4 (3), 365-381, 2023 | 8 | 2023 |
DrugMap: A quantitative pan-cancer analysis of cysteine ligandability M Takahashi, HB Chong, S Zhang, TY Yang, MJ Lazarov, S Harry, ... Cell 187 (10), 2536-2556. e30, 2024 | 6 | 2024 |
EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion–positive cholangiocarcinoma. Cancer Discov. 2022; 12 (5): 1378–1395. doi: 10.1158 … Q Wu, Y Zhen, L Shi, P Vu, P Greninger, R Adil CD-21-1168, 0 | 6 | |